
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY
I Background Information:
A 510(k) Number
K203527
B Applicant
Immunalysis Corporation
C Proprietary and Established Names
Immunalysis Tapentadol Urine HEIATM
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 862.3650 - TX - Clinical
DJG Class II
Opiate Test System Toxicology
II Submission/Device Overview:
A Purpose for Submission:
New Device
B Measurand:
Tapentadol
C Type of Test:
Qualitative and Semi-quantitative Enzyme Immunoassay
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
DJG			Class II	21 CFR 862.3650 -
Opiate Test System			TX - Clinical
Toxicology

--- Page 2 ---
B Indication(s) for Use:
For in vitro diagnostic use.
The Immunalysis Tapentadol Urine HEIATM is a homogeneous enzyme immunoassay with a
cutoff of 200 ng/mL. The assay is intended for use in laboratories for the qualitative and semi-
quantitative analysis of tapentadol in human urine with automated clinical chemistry analyzers.
This assay is calibrated against tapentadol. This in vitro diagnostic device is for prescription use
only.
The Immunalysis Tapentadol Urine HEIATM provides only a preliminary analytical test result. A
more specific alternate chemical method must be used in order to obtain a confirmed analytical
result. Gas Chromatography/ Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem
Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method.
Clinical consideration and professional judgment should be applied to any test result, particularly
when preliminary positive results are used.
The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate
dilution of the specimen for confirmation using a confirmatory method such as Gas
Chromatography/ Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS).
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
Beckman Coulter AU 480 chemistry analyzer.
IV Device/System Characteristics:
A Device Description:
The Immunalysis Tapentadol Urine HEIATM consists of ready to use reagents as follows:
• 1 bottle (25 mL, 60 mL, 100 mL, or 500 mL) of Antibody/Substrate Reagent (Reagent A)
containing recombinant antibodies to Tapentadol, glucose-6-phosphate (G6P) and
nicotinamide adenine dinucleotide (NAD) (<0.5%) in Tris buffer with Sodium Azide as a
preservative.
• 1 bottle (25 mL, 60 mL, 100 mL, or 500 mL) of Enzyme Conjugate Reagent (Reagent E)
containing glucose-6-phosphate dehydrogenase (G6PDH) labeled with tapentadol (<0.5%)
in Tris buffer with Sodium Azide as a preservative.
K203527 - Page 2 of 15

--- Page 3 ---
B Principle of Operation:
The assay is based on the competition of tapentadol labeled enzyme glucose-6-phosphate
dehydrogenase (G6PDH) and the free drug in the urine sample for the fixed amount of rabbit
anti-tapentadol antibody binding sites. In the absence of the free drug in the sample, the antibody
binds the drug enzyme conjugate and enzyme activity is inhibited. This creates a dose response
relationship between drug concentration in the urine and enzyme activity. The enzyme G6PDH
activity is determined at 340 nm spectrophotometrically by the conversion of NAD to NADH.
V Substantial Equivalence Information:
A Predicate Device Name(s):
Immunalysis Tramadol Urine Enzyme Immunoassay
B Predicate 510(k) Number(s):
K141803
C Comparison with Predicate(s):
Device & Predicate
K203527 K141803
Device(s):
Immunalysis
Immunalysis Tramadol Enzyme
Device Trade Name Tapentadol Urine
Immunoassay
HEIATM
General Device
Characteristic Similarities
Same For the qualitative and semi-
Intended Use quantitative analysis of an opioid
in human urine with automated
clinical chemistry analyzers.
Test Principle Same Homogeneous enzyme
immunoassay
User Environment Same For use in laboratories
Sample Matrix Same Human urine
Mass Spectrometry Same Required for preliminary positive
Confirmation analytical results
General Device
Characteristic Differences
Antibody Recombinant FAB Goat Polyclonal Antibody to
antibody to Tapentadol Tramadol
Calibrator Tapentadol Tramadol
K203527 - Page 3 of 15

[Table 1 on page 3]
	Device & Predicate		K203527	K141803
	Device(s):			
Device Trade Name			Immunalysis
Tapentadol Urine
HEIATM	Immunalysis Tramadol Enzyme
Immunoassay
	General Device			
	Characteristic Similarities			
Intended Use			Same	For the qualitative and semi-
quantitative analysis of an opioid
in human urine with automated
clinical chemistry analyzers.
Test Principle			Same	Homogeneous enzyme
immunoassay
User Environment			Same	For use in laboratories
Sample Matrix			Same	Human urine
Mass Spectrometry
Confirmation			Same	Required for preliminary positive
analytical results
	General Device			
	Characteristic Differences			
Antibody			Recombinant FAB
antibody to Tapentadol	Goat Polyclonal Antibody to
Tramadol
Calibrator			Tapentadol	Tramadol

--- Page 4 ---
VI Standards/Guidance Documents Referenced:
• ISO 14971:2007 Medical Devices – Application of Risk Management to Medical Devices
• EN ISO 14971:2012 Medical Devices – Application of Risk Management to Medical
Devices
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
A precision study was performed over 20 days, two runs per day in duplicates (20 x 2 x 2
replicates per panel member) for a total of 80 replicates (N=80) per sample on 3 lots of
reagent. Nine panel members were prepared using drug free negative urine as the base
sample and 8 panel members were spiked to concentrations of assay cutoff and ±25%, ±50%,
±75%, ±100% of the cutoff (200 ng/mL). The concentrations used for spiking were
confirmed by liquid chromatography tandem mass spectrometry (LC-MS/MS).
Summary of Precision – Qualitative
Concentration % of cutoff # of determinations Result
(ng/mL)
Lot# 1
0 -100% 80 80 Negative
50 -75% 80 80 Negative
100 -50% 80 80 Negative
150 -25% 80 80 Negative
200 Cutoff 80 41 Neg / 39 Pos
250 +25% 80 80 Positive
300 +50% 80 80 Positive
350 +75% 80 80 Positive
400 +100% 80 80 Positive
Lot# 2
0 -100% 80 80 Negative
50 -75% 80 80 Negative
100 -50% 80 80 Negative
150 -25% 80 80 Negative
200 Cutoff 80 35 Neg / 45 Pos
250 +25% 80 80 Positive
300 +50% 80 80 Positive
350 +75% 80 80 Positive
400 +100% 80 80 Positive
K203527 - Page 4 of 15

[Table 1 on page 4]
Concentration
(ng/mL)	% of cutoff	# of determinations	Result
Lot# 1			
0	-100%	80	80 Negative
50	-75%	80	80 Negative
100	-50%	80	80 Negative
150	-25%	80	80 Negative
200	Cutoff	80	41 Neg / 39 Pos
250	+25%	80	80 Positive
300	+50%	80	80 Positive
350	+75%	80	80 Positive
400	+100%	80	80 Positive
Lot# 2			
0	-100%	80	80 Negative
50	-75%	80	80 Negative
100	-50%	80	80 Negative
150	-25%	80	80 Negative
200	Cutoff	80	35 Neg / 45 Pos
250	+25%	80	80 Positive
300	+50%	80	80 Positive
350	+75%	80	80 Positive
400	+100%	80	80 Positive

--- Page 5 ---
Concentration % of cutoff # of determinations Result
(ng/mL)
Lot# 3
0 -100% 80 80 Negative
50 -75% 80 80 Negative
100 -50% 80 80 Negative
150 -25% 80 80 Negative
200 Cutoff 80 42 Neg / 38 Pos
250 +25% 80 80 Positive
300 +50% 80 80 Positive
350 +75% 80 80 Positive
400 +100% 80 80 Positive
Summary of Precision - Semi-Quantitative
Mean Qualitative
Concentration % of # of
Conc. Interpretative SD CV (%)
(ng/mL) cutoff determinations
(ng/mL) Result
Lot# 1
0 -100% 80 -3 80 Negative 8.0 N/A
50 -75% 80 48 80 Negative 4.7 9.7
100 -50% 80 99 80 Negative 7.5 7.6
150 -25% 80 161 80 Negative 5.8 3.6
200 Cutoff 80 215 2 Neg / 78 Pos 8.6 4.0
250 +25% 80 268 80 Positive 10.0 3.7
300 +50% 80 304 80 Positive 17.6 5.8
350 +75% 80 372 80 Positive 25.4 6.8
400 +100% 80 431 80 Positive 25.2 5.9
Lot# 2
0 -100% 80 -4 80 Negative 8.9 N/A
50 -75% 80 50 80 Negative 4.8 9.7
100 -50% 80 100 80 Negative 7.8 7.7
150 -25% 80 162 80 Negative 7.6 4.7
200 Cutoff 80 213 8 Neg / 72 Pos 10.6 5.0
250 +25% 80 263 80 Positive 12.3 4.7
300 +50% 80 298 80 Positive 17.6 5.9
350 +75% 80 359 80 Positive 20.2 5.6
400 +100% 80 417 80 Positive 21.7 5.2
Lot# 3
0 -100% 80 -3 80 Negative 7.1 N/A
50 -75% 80 49 80 Negative 4.4 8.9
100 -50% 80 102 80 Negative 6.9 6.8
K203527 - Page 5 of 15

[Table 1 on page 5]
Concentration
(ng/mL)	% of cutoff	# of determinations	Result
Lot# 3			
0	-100%	80	80 Negative
50	-75%	80	80 Negative
100	-50%	80	80 Negative
150	-25%	80	80 Negative
200	Cutoff	80	42 Neg / 38 Pos
250	+25%	80	80 Positive
300	+50%	80	80 Positive
350	+75%	80	80 Positive
400	+100%	80	80 Positive

[Table 2 on page 5]
Concentration
(ng/mL)	% of
cutoff	# of
determinations	Mean
Conc.
(ng/mL)	Qualitative
Interpretative
Result	SD	CV (%)
Lot# 1						
0	-100%	80	-3	80 Negative	8.0	N/A
50	-75%	80	48	80 Negative	4.7	9.7
100	-50%	80	99	80 Negative	7.5	7.6
150	-25%	80	161	80 Negative	5.8	3.6
200	Cutoff	80	215	2 Neg / 78 Pos	8.6	4.0
250	+25%	80	268	80 Positive	10.0	3.7
300	+50%	80	304	80 Positive	17.6	5.8
350	+75%	80	372	80 Positive	25.4	6.8
400	+100%	80	431	80 Positive	25.2	5.9
Lot# 2						
0	-100%	80	-4	80 Negative	8.9	N/A
50	-75%	80	50	80 Negative	4.8	9.7
100	-50%	80	100	80 Negative	7.8	7.7
150	-25%	80	162	80 Negative	7.6	4.7
200	Cutoff	80	213	8 Neg / 72 Pos	10.6	5.0
250	+25%	80	263	80 Positive	12.3	4.7
300	+50%	80	298	80 Positive	17.6	5.9
350	+75%	80	359	80 Positive	20.2	5.6
400	+100%	80	417	80 Positive	21.7	5.2
Lot# 3						
0	-100%	80	-3	80 Negative	7.1	N/A
50	-75%	80	49	80 Negative	4.4	8.9
100	-50%	80	102	80 Negative	6.9	6.8

--- Page 6 ---
Mean Qualitative
Concentration % of # of
Conc. Interpretative SD CV (%)
(ng/mL) cutoff determinations
(ng/mL) Result
150 -25% 80 162 80 Negative 6.1 3.8
200 Cutoff 80 215 7 Neg / 73 Pos 9.7 4.5
250 +25% 80 266 80 Positive 9.9 3.7
300 +50% 80 303 80 Positive 16.0 5.3
350 +75% 80 369 80 Positive 20.7 5.6
400 +100% 80 422 80 Positive 20.6 4.9
2. Linearity:
A linearity study in the semi-quantitative mode was conducted by spiking a drug free urine
pool with a high concentration of tapentadol above the highest calibrator. Additional linearity
samples were made by serially diluting the high concentration specimen with drug free urine
to achieve concentrations ranging from 100 to 1100 ng/mL. The 0 ng/mL specimen was
made from drug free urine. Each pool was tested in triplicate to calculate the mean
concentration values that were used to calculate drug recovery of tapentadol. The assay drug
recovery percentage ranged from 95.8 to 110.4 %. Linearity test results in semi-quantitative
mode are presented below.
Linearity/Recovery – Tapentadol
Expected Mean Recovery (%)
Concentration Concentration
(ng/mL) (ng/mL)
0 3.0 N/A
100 110.4 110.4
200 211.6 105.8
300 298.2 99.4
400 417.3 104.3
500 531.2 106.2
600 614.1 102.4
700 721.7 103.1
800 827.3 103.4
900 907.8 100.9
1000 980.1 98.0
1100 1054.3 95.8
K203527 - Page 6 of 15

[Table 1 on page 6]
Concentration
(ng/mL)	% of
cutoff	# of
determinations	Mean
Conc.
(ng/mL)	Qualitative
Interpretative
Result	SD	CV (%)
150	-25%	80	162	80 Negative	6.1	3.8
200	Cutoff	80	215	7 Neg / 73 Pos	9.7	4.5
250	+25%	80	266	80 Positive	9.9	3.7
300	+50%	80	303	80 Positive	16.0	5.3
350	+75%	80	369	80 Positive	20.7	5.6
400	+100%	80	422	80 Positive	20.6	4.9

[Table 2 on page 6]
Expected
Concentration
(ng/mL)	Mean
Concentration
(ng/mL)	Recovery (%)
0	3.0	N/A
100	110.4	110.4
200	211.6	105.8
300	298.2	99.4
400	417.3	104.3
500	531.2	106.2
600	614.1	102.4
700	721.7	103.1
800	827.3	103.4
900	907.8	100.9
1000	980.1	98.0
1100	1054.3	95.8

--- Page 7 ---
3. Analytical Specificity/Interference:
Cross Reactivity
Structurally and functionally similar compounds were spiked into drug free urine at levels
that will yield a result that is equivalent to the cutoff. The data demonstrates all sample
compounds tested were negative by both the qualitative and semi-quantitative interpretations
except for N-desmethyl tapentadol and tapentadol glucuronide. The % of cross- reactivity of
the semi-quantitative results was < 0.2 % for all compounds tested except for N-desmethyl
tapentadol with 15.7% and tapentadol glucuronide with 0.5% of cross- reactivity. Cross-
reactivity test results in qualitative mode and semi-quantitative mode are presented in below.
Cross-Reactivity – Qualitative
Tapentadol
Compound Cross-
Compound Equivalent Result
Conc. ng/mL) Reactivity
Conc.
(%)
(ng/mL)
Chlorpromazine 100,000 < 200 NEG <0.2
Clomipramine 100,000 <200 NEG <0.2
Cyclobenzaprine 100,000 <200 NEG <0.2
Doxepin 100,000 <200 NEG <0.2
Imipramine 100,000 <200 NEG <0.2
O-desmethyl tramadol 100,000 <200 NEG <0.2
O-desmethyl venlafaxine 100,000 <200 NEG <0.2
N-desmethyl tapentadol 1,275 200 POS 15.7
N-desmethyl tramadol 100,000 <200 NEG <0.2
N-desmethyl venlafaxine 100,000 <200 NEG <0.2
Tapentadol glucuronide 43,000 200 POS 0.5
Tramadol 100,000 <200 NEG <0.2
Trimipramine 100,000 <200 NEG <0.2
Venlafaxine 100,000 <200 NEG <0.2
Cross-Reactivity – Semi-Quantitative
Compound Tapentadol Mean
Compound Conc. Equivalent Value Result Cross-
(ng/mL) Conc. (ng/mL) Reactivity
(ng/mL) (%)
Chlorpromazine 100,000 < 200 47.3 NEG <0.2
Clomipramine 100,000 <200 47.6 NEG <0.2
Cyclobenzaprine 100,000 <200 1.0 NEG <0.2
Doxepin 100,000 <200 0.9 NEG <0.2
Imipramine 100,000 <200 69.7 NEG <0.2
K203527 - Page 7 of 15

[Table 1 on page 7]
Compound	Compound
Conc. ng/mL)	Tapentadol
Equivalent
Conc.
(ng/mL)	Result	Cross-
Reactivity
(%)
Chlorpromazine	100,000	< 200	NEG	<0.2
Clomipramine	100,000	<200	NEG	<0.2
Cyclobenzaprine	100,000	<200	NEG	<0.2
Doxepin	100,000	<200	NEG	<0.2
Imipramine	100,000	<200	NEG	<0.2
O-desmethyl tramadol	100,000	<200	NEG	<0.2
O-desmethyl venlafaxine	100,000	<200	NEG	<0.2
N-desmethyl tapentadol	1,275	200	POS	15.7
N-desmethyl tramadol	100,000	<200	NEG	<0.2
N-desmethyl venlafaxine	100,000	<200	NEG	<0.2
Tapentadol glucuronide	43,000	200	POS	0.5
Tramadol	100,000	<200	NEG	<0.2
Trimipramine	100,000	<200	NEG	<0.2
Venlafaxine	100,000	<200	NEG	<0.2

[Table 2 on page 7]
Compound	Compound
Conc.
(ng/mL)	Tapentadol
Equivalent
Conc.
(ng/mL)	Mean
Value
(ng/mL)	Result	Cross-
Reactivity
(%)
Chlorpromazine	100,000	< 200	47.3	NEG	<0.2
Clomipramine	100,000	<200	47.6	NEG	<0.2
Cyclobenzaprine	100,000	<200	1.0	NEG	<0.2
Doxepin	100,000	<200	0.9	NEG	<0.2
Imipramine	100,000	<200	69.7	NEG	<0.2

--- Page 8 ---
Compound Tapentadol Mean
Compound Conc. Equivalent Value Result Cross-
(ng/mL) Conc. (ng/mL) Reactivity
(ng/mL) (%)
O-desmethyl tramadol 100,000 <200 101.0 NEG <0.2
O-desmethyl venlafaxine 100,000 <200 1.8 NEG <0.2
N-desmethyl tapentadol 1,275 200 214.3 POS 15.7
N-desmethyl tramadol 100,000 <200 6.0 NEG <0.2
N-desmethyl venlafaxine 100,000 <200 1.9 NEG <0.2
Tapentadol glucuronide 43,000 200 211.7 POS 0.5
Tramadol 100,000 <200 2.5 NEG <0.2
Trimipramine 100,000 <200 10.8 NEG <0.2
Venlafaxine 100,000 <200 -1.6 NEG <0.2
Interference – Structurally Unrelated Compounds
Structurally unrelated compounds were evaluated in qualitative and semi-quantitative modes
by spiking the potential interferent into drug free urine containing tapentadol at ±25% of the
cutoff. The levels of structurally unrelated compounds that did not interfere in the assay are
presented below.
Non-Interfering Structurally Unrelated Compounds
Compound Conc. Tested
(ng/mL)
4-Bromo-2,5,Dimethoxyphenethylamine 100,000
6-Acetylcodeine 100,000
6-Acetylmorphine 100,000
Alprazolam 100,000
7-Aminoclonazepam 100,000
7-Aminoflunitrazepam 100,000
7-Aminonitrazepam 100,000
Amitriptyline 100,000
d-Amphetamine 100,000
Amobarbital 100,000
Atomoxetine 100,000
Benzoylecgonine 100,000
Benzylpiperazine 100,000
Bromazepam 100,000
Brompheniramine 100,000
Buprenorphine 100,000
Bupropion 100,000
Butabarbital 100,000
Butalbital 100,000
K203527 - Page 8 of 15

[Table 1 on page 8]
Compound	Compound
Conc.
(ng/mL)	Tapentadol
Equivalent
Conc.
(ng/mL)	Mean
Value
(ng/mL)	Result	Cross-
Reactivity
(%)
O-desmethyl tramadol	100,000	<200	101.0	NEG	<0.2
O-desmethyl venlafaxine	100,000	<200	1.8	NEG	<0.2
N-desmethyl tapentadol	1,275	200	214.3	POS	15.7
N-desmethyl tramadol	100,000	<200	6.0	NEG	<0.2
N-desmethyl venlafaxine	100,000	<200	1.9	NEG	<0.2
Tapentadol glucuronide	43,000	200	211.7	POS	0.5
Tramadol	100,000	<200	2.5	NEG	<0.2
Trimipramine	100,000	<200	10.8	NEG	<0.2
Venlafaxine	100,000	<200	-1.6	NEG	<0.2

[Table 2 on page 8]
Compound	Conc. Tested
(ng/mL)
4-Bromo-2,5,Dimethoxyphenethylamine	100,000
6-Acetylcodeine	100,000
6-Acetylmorphine	100,000
Alprazolam	100,000
7-Aminoclonazepam	100,000
7-Aminoflunitrazepam	100,000
7-Aminonitrazepam	100,000
Amitriptyline	100,000
d-Amphetamine	100,000
Amobarbital	100,000
Atomoxetine	100,000
Benzoylecgonine	100,000
Benzylpiperazine	100,000
Bromazepam	100,000
Brompheniramine	100,000
Buprenorphine	100,000
Bupropion	100,000
Butabarbital	100,000
Butalbital	100,000

--- Page 9 ---
Compound Conc. Tested
(ng/mL)
Cannabidiol 100,000
Cannabinol 100,000
Carbamazepine 100,000
Cetirizine 100,000
Chlordiazepoxide 100,000
1-(3-Chlorophenylpiperazine) mCPP 100,000
Chlorpheniramine 100,000
Cimetidine 100,000
Citalopram 100,000
Clobazam 100,000
Clonazepam 100,000
Clozapine 100,000
Cocaine 100,000
Codeine 100,000
Cotinine 100,000
Dehydronorketamine 50,000
Demoxepam 100,000
Desakylflurazepam 100,000
Desipramine 100,000
Dextromethorphan 100,000
Dihydrohydroxcarbamazepine 100,000
Diazepam 100,000
Digoxin 100,000
Dihydrocodeine 100,000
Doxylamine 100,000
Duloxetine 100,000
Ecgonine 100,000
Ecgonine Methyl Ester 100,000
EDDP 100,000
EMDP 100,000
1S,2R (+)-Ephedrine 100,000
Ethylmorphine 100,000
Ethyl-β-D-Glucuronide 100,000
Fentanyl 100,000
Fenfluramine 100,000
Flunitrazepam 100,000
Fluoxetine 100,000
Flurazepam 100,000
Haloperidol 100,000
Heroin 100,000
K203527 - Page 9 of 15

[Table 1 on page 9]
Compound	Conc. Tested
(ng/mL)
Cannabidiol	100,000
Cannabinol	100,000
Carbamazepine	100,000
Cetirizine	100,000
Chlordiazepoxide	100,000
1-(3-Chlorophenylpiperazine) mCPP	100,000
Chlorpheniramine	100,000
Cimetidine	100,000
Citalopram	100,000
Clobazam	100,000
Clonazepam	100,000
Clozapine	100,000
Cocaine	100,000
Codeine	100,000
Cotinine	100,000
Dehydronorketamine	50,000
Demoxepam	100,000
Desakylflurazepam	100,000
Desipramine	100,000
Dextromethorphan	100,000
Dihydrohydroxcarbamazepine	100,000
Diazepam	100,000
Digoxin	100,000
Dihydrocodeine	100,000
Doxylamine	100,000
Duloxetine	100,000
Ecgonine	100,000
Ecgonine Methyl Ester	100,000
EDDP	100,000
EMDP	100,000
1S,2R (+)-Ephedrine	100,000
Ethylmorphine	100,000
Ethyl-β-D-Glucuronide	100,000
Fentanyl	100,000
Fenfluramine	100,000
Flunitrazepam	100,000
Fluoxetine	100,000
Flurazepam	100,000
Haloperidol	100,000
Heroin	100,000

--- Page 10 ---
Compound Conc. Tested
(ng/mL)
Hexobarbital 100,000
Hydrocodone 100,000
Hydromorphone 100,000
Ketamine 100,000
Lamotrigine 100,000
Levorphanol 100,000
Lidocaine 100,000
Lorazepam 100,000
Lorazepam Glucuronide 50,000
Lormetazepam 100,000
LSD 100,000
Maprotiline 100,000
MDA 100,000
MDEA 100,000
MDMA 100,000
Meperidine 100,000
Meprobamate 100,000
d-Methamphetamine 100,000
Methaquolone 100,000
Methoxetamine 100,000
Methylone 100,000
Methylphenidate 100,000
Midazolam 100,000
Morphine 100,000
Morphine-3-Glucuronide 100,000
Morphine-6-Glucuronide 100,000
Nalorphine 100,000
Naloxone 100,000
Naltrexone 100,000
Naproxen 100,000
Nitrazepam 100,000
Norbuprenorphine 100,000
Norcodeine 100,000
Nordiazepam 100,000
Norketamine 100,000
Normorphine 100,000
Noroxycodone 100,000
Norpropoxyphene 100,000
Norpseudoephedrine 100,000
Nortriptyline 100,000
K203527 - Page 10 of 15

[Table 1 on page 10]
Compound	Conc. Tested
(ng/mL)
Hexobarbital	100,000
Hydrocodone	100,000
Hydromorphone	100,000
Ketamine	100,000
Lamotrigine	100,000
Levorphanol	100,000
Lidocaine	100,000
Lorazepam	100,000
Lorazepam Glucuronide	50,000
Lormetazepam	100,000
LSD	100,000
Maprotiline	100,000
MDA	100,000
MDEA	100,000
MDMA	100,000
Meperidine	100,000
Meprobamate	100,000
d-Methamphetamine	100,000
Methaquolone	100,000
Methoxetamine	100,000
Methylone	100,000
Methylphenidate	100,000
Midazolam	100,000
Morphine	100,000
Morphine-3-Glucuronide	100,000
Morphine-6-Glucuronide	100,000
Nalorphine	100,000
Naloxone	100,000
Naltrexone	100,000
Naproxen	100,000
Nitrazepam	100,000
Norbuprenorphine	100,000
Norcodeine	100,000
Nordiazepam	100,000
Norketamine	100,000
Normorphine	100,000
Noroxycodone	100,000
Norpropoxyphene	100,000
Norpseudoephedrine	100,000
Nortriptyline	100,000

--- Page 11 ---
Compound Conc. Tested
(ng/mL)
Olanzapine 100,000
Oxazepam 100,000
Oxazepam glucuronide 50,000
Oxycodone 100,000
Oxymorphone 100,000
Delta-9-THC 100,000
11-hydroxy-delta-9-THC 100,000
11-nor-9 carboxy THC 100,000
PCP 100,000
Pentazocine 100,000
Pentobarbital 100,000
Phenobarbital 100,000
Phentermine 100,000
R(-)-Phenylephrine 100,000
Phenylpropanolamine (PPA) 100,000
Phenytoin 100,000
PMA 100,000
PMMA 100,000
Prazepam 100,000
Propoxyphene 100,000
Propranolol 100,000
Protriptyline 100,000
R,R (-)-Pseudoephedrine 100,000
S,S (+)-Pseudoephedrine 100,000
Risperidone 100,000
Ritalinic Acid 100,000
Salicylic Acid 100,000
Secobarbital 100,000
Sertraline 100,000
Sufentanil 50,000
Temazepam 100,000
Theophylline 100,000
Thioridazine 100,000
Trazadone 100,000
Triazolam 100,000
3-Trifluoromethylphenyl-piperazine 100,000
Tyramine 100,000
Verapamil 100,000
Zolpidem 100,000
Carisoprodol 100,000
K203527 - Page 11 of 15

[Table 1 on page 11]
Compound	Conc. Tested
(ng/mL)
Olanzapine	100,000
Oxazepam	100,000
Oxazepam glucuronide	50,000
Oxycodone	100,000
Oxymorphone	100,000
Delta-9-THC	100,000
11-hydroxy-delta-9-THC	100,000
11-nor-9 carboxy THC	100,000
PCP	100,000
Pentazocine	100,000
Pentobarbital	100,000
Phenobarbital	100,000
Phentermine	100,000
R(-)-Phenylephrine	100,000
Phenylpropanolamine (PPA)	100,000
Phenytoin	100,000
PMA	100,000
PMMA	100,000
Prazepam	100,000
Propoxyphene	100,000
Propranolol	100,000
Protriptyline	100,000
R,R (-)-Pseudoephedrine	100,000
S,S (+)-Pseudoephedrine	100,000
Risperidone	100,000
Ritalinic Acid	100,000
Salicylic Acid	100,000
Secobarbital	100,000
Sertraline	100,000
Sufentanil	50,000
Temazepam	100,000
Theophylline	100,000
Thioridazine	100,000
Trazadone	100,000
Triazolam	100,000
3-Trifluoromethylphenyl-piperazine	100,000
Tyramine	100,000
Verapamil	100,000
Zolpidem	100,000
Carisoprodol	100,000

--- Page 12 ---
Compound Conc. Tested
(ng/mL)
1R,2S (-)-Ephedrine 100,000
Acetaminophen 500,000
Acetylsalicyclic Acid 500,000
α-hydroxyalprazolam 100,000
Barbital 100,000
Caffeine 500,000
Cyclopentobarbital 100,000
Diphenhydramine 300,000
Ibuprofen 500,000
LAAM 100,000
Labetalol 100,000
Loratadine 100,000
Mephenytoin 100,000
Methadone 500,000
Methylphenylsuccinimide (mCPP) 100,000
Mirtazapine 100,000
n-desmethylcitalopram 100,000
Nor-LAAM 100,000
Noroxymorphone 100,000
Normesuximide 100,000
PEMA 100,000
Phenazepam 100,000
Procaine 100,000
Interference – Endogenous Compounds and Urine Preservatives
Endogenous compounds and urine preservatives were evaluated in qualitative and semi-
quantitative modes by spiking the potential interferent into drug free urine containing
tapentadol at ±25% of the cutoff. Due to the interference of boric acid observed at ±25% of
the cutoff, potential interference was also evaluated at ±50% of the cutoff. Endogenous
compounds and urine preservative tested that did not interfere in the assay are presented
below.
K203527 - Page 12 of 15

[Table 1 on page 12]
Compound	Conc. Tested
(ng/mL)
1R,2S (-)-Ephedrine	100,000
Acetaminophen	500,000
Acetylsalicyclic Acid	500,000
α-hydroxyalprazolam	100,000
Barbital	100,000
Caffeine	500,000
Cyclopentobarbital	100,000
Diphenhydramine	300,000
Ibuprofen	500,000
LAAM	100,000
Labetalol	100,000
Loratadine	100,000
Mephenytoin	100,000
Methadone	500,000
Methylphenylsuccinimide (mCPP)	100,000
Mirtazapine	100,000
n-desmethylcitalopram	100,000
Nor-LAAM	100,000
Noroxymorphone	100,000
Normesuximide	100,000
PEMA	100,000
Phenazepam	100,000
Procaine	100,000

--- Page 13 ---
Non-interfering Endogenous Compounds
Compound Concentration
Tested
Acetone 1.0 g/dL
Ascorbic Acid 1.5 g/dL
Bilirubin 0.002 g/dL
Creatinine 0.5 g/dL
Ethanol 1.0 g/dL
Galactose 0.01 g/dL
γ-Globulin 0.5 g/dL
Glucose 2.0 g/dL
Hemoglobin 0.3 g/dL
Human Serum 0.5 g/dL
Albumin
Oxalic Acid 0.1 g/dL
Riboflavin 0.0075 g/dL
Sodium Chloride 6.0 g/dL
Urea 6.0 g/dL
Non-interfering Urine Preservative
Compound Concentration
Tested
Sodium Azide 1% w/v
Sodium 1% w/v
Fluoride
Boric acid interference test results at ±50% of the cutoff in qualitative and semi-quantitative
modes are presented in below.
Interference at ±50% of the Cutoff
-50% Cutoff (50 ng/mL) +50% Cutoff (150 ng/mL)
Concentration
Semi- Semi-
Compound Tested Qualitative Qualitative
Quantitative Quantitative
Result Result
Result Result
Boric Acid 1% w/v Negative Negative Negative Negative
The sponsor includes the following limitation in the labeling: “Boric Acid at 1% w/v may
cause false negative results. The assay should not be used to test samples which contain boric
acid.”
K203527 - Page 13 of 15

[Table 1 on page 13]
Compound	Concentration
Tested
Acetone	1.0 g/dL
Ascorbic Acid	1.5 g/dL
Bilirubin	0.002 g/dL
Creatinine	0.5 g/dL
Ethanol	1.0 g/dL
Galactose	0.01 g/dL
γ-Globulin	0.5 g/dL
Glucose	2.0 g/dL
Hemoglobin	0.3 g/dL
Human Serum
Albumin	0.5 g/dL
Oxalic Acid	0.1 g/dL
Riboflavin	0.0075 g/dL
Sodium Chloride	6.0 g/dL
Urea	6.0 g/dL

[Table 2 on page 13]
Compound	Concentration
Tested
Sodium Azide	1% w/v
Sodium
Fluoride	1% w/v

[Table 3 on page 13]
Compound	Concentration
Tested	-50% Cutoff (50 ng/mL)		+50% Cutoff (150 ng/mL)	
		Qualitative
Result	Semi-
Quantitative
Result	Qualitative
Result	Semi-
Quantitative
Result
Boric Acid	1% w/v	Negative	Negative	Negative	Negative

--- Page 14 ---
Interference – pH
To evaluate potential interference from the effect of urine pH on the assay’s ability to detect
tapentadol, device performance in the qualitative and semi-quantitative modes was tested
using a range of urine pH values (3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 and 11.0). All test
samples were prepared in drug free urine containing tapentadol at ±25% of the cutoff. No
positive or negative interference was observed at urine pH values ranging from 3.0 to 11.0
for each test mode.
4. Assay Reportable Range:
Not applicable
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
The assay calibrators are traceable to a commercially-available, certified, standard material
with the concentration verified by GC-MS or LC-MS/MS.
6. Detection Limit:
Not applicable
7. Assay Cut-Off:
The assay cut-off is 200ng/mL of tapentadol in urine.
B Comparison Studies:
1. Method Comparison with Predicate Device:
A method comparison study was performed using 160 deidentified remnant unaltered clinical
urine samples obtained from clinical testing laboratories. The urine samples were analyzed
for tapentadol using the Immunalysis Tapentadol Urine HEIA on the Beckman Coulter
AU480 chemistry analyzer in both qualitative and semi-quantitative modes and LC-MS/MS
(Agilent 6430 Liquid Chromatography-Tandem Mass Spectrometry). The method results of
the comparison study showed a positive percent agreement (PPA) and negative percent
agreement (NPA) of 100% and 100%, respectively. The results are presented below.
K203527 - Page 14 of 15

--- Page 15 ---
Method Comparison Results by Concentration Range
LC-MS/MS Tapentadol Concentration
Immunalysis < 100 100 – 199 200 - 300 > 300
Tapentadol Urine ng/mL ng/mL ng/mL ng/mL
HEIA Result (less than (between - (between (greater
-50% 50% cutoff and than +50%
cutoff) cutoff +50% cutoff)
and cutoff)
cutoff)
Qualitative Positive 0 0 14 81
Negative 46 19 0 0
Semi- Positive 0 0 14 81
Quantitative Negative 46 19 0 0
2. Matrix Comparison:
Not applicable. The assay is intended for use only with urine samples.
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable
2. Clinical Specificity:
Not applicable
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable
D Clinical Cut-Off:
Not applicable
E Expected Values/Reference Range:
Not applicable
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.
K203527 - Page 15 of 15

[Table 1 on page 15]
Immunalysis
Tapentadol Urine
HEIA Result		LC-MS/MS Tapentadol Concentration			
		< 100
ng/mL
(less than
-50%
cutoff)	100 – 199
ng/mL
(between -
50%
cutoff
and
cutoff)	200 - 300
ng/mL
(between
cutoff and
+50%
cutoff)	> 300
ng/mL
(greater
than +50%
cutoff)
Qualitative	Positive	0	0	14	81
	Negative	46	19	0	0
Semi-
Quantitative	Positive	0	0	14	81
	Negative	46	19	0	0